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Dual inhibitor studies were performed to examine the interaction of aphidicolin, phosphonoformate,
9-(2-hydroxyethoxymethyl)guanine triphosphate, and 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphos-
phate with herpes simplex virus DNA polymerase. Kinetic data indicated that inhibition by one agent prevents
simultaneous inhibition by a second agent, producing a mutually exclusive inhibition pattern. This suggested
that binding sites on the DNA polymerase molecule for these compounds are kinetically overlapping. These
findings should be taken into consideration for the design of future antiviral compounds and combination
chemotherapy protocols.
Herpes simplex virus (HSV) DNA polymerase is a logical
target for the development of antiviral drugs since it is
necessary for viral replication and is biochemically distinct
from host DNA polymerases. Several classes of antiherpetic
agents have been developed which interact with virus DNA
polymerase. They can be grouped according to mechanism
of interaction as follows. (i) The first group is nucleoside
analogs; these compounds are phosphorylated in virus-in-
fected cells and interact with virus DNA polymerase as
nucleoside triphosphates (NTPs) by competing with natu-
rally occurring deoxynucleoside triphosphates (dNTPs) as
substrate for incorporation into replicating DNA. The nucle-
osides 9-(2-hydroxyethoxymethyl)guanine (ACG; acyclovir)
and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) are
examples which, as NTPs (ACGTP and DHPGTP), compete
with dGTP for incorporation into DNA (10, 12, 15, 17). (ii)
Aphidicolin and its derivatives make up the second group;
aphidicolin has been found to competitively inhibit incorpo-
ration of dATP, dCTP, and dTTP by virus DNA polymerase
into activated DNA template (13), but is noncompetitive
with dGTP and uncompetitive with low concentrations. of
DNA (13, 21). (iii) Pyrophosphate analogs constitute the
third group; compounds such as phosphonoacetate and its
cogener phosphonoformate (PFA) inhibit pyrophosphoro-
lysis competitively with pyrophosphate but are noncompet-
itive with dNTPs and uncompetitive with DNA (9, 11, 20,
22).
It appears that these three classes of compounds interact
with virus DNA polymerase by different mechanisms. Sev-
eral laboratories have investigated the inhibition of virus
replication in culture by combinations of these compounds.
In the case of phosphonoacetate and ACG, antiviral syner-
gism has been observed (7, 26). Other studies indicate that
resistance to PFA can result in both collateral hypersensi-
tivity to aphidicolin (2, 4, 18) and cross-resistance to ACG
(5, 6, 8, 14, 19, 24). It is not clear why resistance to one class
of compound affects resistance to a different class of com-
pound. One possibility is that binding sites on the DNA
polymerase molecule for these compounds are closely asso-
ciated. To investigate this possibility, we examined the
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kinetic interaction of HSV DNA polymerase with combina-
tions of ACGTP, DHPGTP, aphidicolin, and PFA. The
results are presented in this communication.
MATERIALS AND METHODS
Chemicals. All chemicals used were reagent grade or bet-
ter. dNTPs, calf thymus DNA, PFA, and bovine serum
albumin were purchased from Sigma Chemical Co., St.
Louis, Mo. 3H-labeled dNTPs were purchased from ICN
Pharmaceuticals Inc., Irvine, Calif. Aphidicolin was ob-
tained from Imperial Chemical Industries Limited, Cheshire,
U.K., dissolved in dimethyl sulfoxide as a 30 mM stock, and
stored at -20°C. ACG was obtained from Wellcome Re-
search Laboratories, Research Triangle Park, N.C. DHPG
was obtained from Syntex Laboratories, Inc., Palo Alto,
Calif.
Substrate preparation. ACG was converted to the triphos-
phate by chemical methods (23), and DHPG was converted
to the triphosphate by using HSV type 1 thymidine kinase
and human erythrocyte lysate as described previously (3).
NTPs were purified by anion-exchange high-pressure liquid
chromatography. Activated DNA was prepared as previ-
ously described (1) and end labeled by incubation with
[3H]dGTP (6 x 103 cpm/pmol) and HSV DNA polymerase
(10). Reactions were terminated by heating to 65°C for 15
min, followed by slow cooling to 23°C. Unincorporated
dNTP was separated from polynucleotide by Sephadex G-25
filtration. Substrate prepared in this manner had 7 x 103
cpm/,ug of nucleotide.
Enzyme purification and assay. DNA polymerase induced
by HSV type 1 (KOS) was purified by DEAE, phosphocel-
lulose, and double-stranded DNA-cellulose chromatography
as previously described (8). The specific activity of enzyme
used in these studies was at least 1.2 x 104 U/mg. Standard
HSV DNA polymerase reaction mixtures contained the
following: 50 mM Tris-hydrochloride, pH 8.0; 4 mM MgCI2;
0.5 mM dithiothreitol; 0.2 mg of bovine serum albumin per
ml; 0.2 M KCl; 10 ,ug of activated calf thymus DNA; 100 ,uM
each dATP, dCTP, and dGTP; and 5 ,uM [3H]dTTP in a
volume of 100 ,ul. One unit of DNA polymerase activity is
defined as the amount of enzyme catalyzing the incorpora-
tion of 1 nmol of dTMP per h at 37°C in the standard assay.
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FIG. 1. Inhibition of virus DNA polymerase by combinations of
PFA and acyclic nucleotide. DNA polymerase (0.03 U) was assayed
under conditions described in the text. PFA was present at the
concentrations indicated. (A) ACGTP was added to produce the
following concentrations: 0 (0), 3 (U), 6 (A), and 9 (0) nM. (B)
DHPGTP was added to produce the following concentrations: 0 (0),
30 (U), 60 (A), and 90 (0) nM. Reaction velocity is expressed as
picomoles of dGMP incorporated per hour. Lines were fitted to the
data by the method of least squares.
For kinetic studies, dATP, dCTP, and dTTP were present
at 100 p.M each and [3H]dGTP (1,000 cpm/pmol) was present
at 0.5 p.M. Aphidicolin, PFA, ACGTP, and DHPGTP were
added at various concentrations, and reactions were allowed
to proceed for either 10 or 20 min at 37°C. Samples of 50 pul
were spotted onto GF/A filter disks and processed to deter-
mine trichloroacetic acid-insoluble radioactivity.
Nuclease assays were performed under conditions identi-
cal to those used for DNA polymerase assays except that
dNTPs were omitted and 2 ,ug of [3H]dGMP end-labeled
DNA was used in place of activated DNA. After incubation
at 37°C for 30 min, trichloroacetic acid-soluble radioactivity
was determined.
RESULTS AND DISCUSSION
To examine the interaction of aphidicolin, PFA, ACGTP,
and DHPGTP with HSV DNA polymera$e, DNA polymer-
ase and polymerase-associated nuclease activity was as-
sayed in the presence of various concentrations of one
inhibitor and different fixed concentrations of a second
inhibitor. The reciprocals of reaction velocities were then
plotted. This method of,analysis has been described by Segel
(25) and is valid for all combinations of inhibitors, whether
competitive or noncompetitive with substrate. The effect of
the second inhibitor upon slopes of the lines observed
indicates whether enzyme is simultaneously inhibited by
both inhibitors or whether inhibition by one agent prevents
inhibition by a second agent. In the former case, addition of
a second inhibitor results in a series of intersecting lines with
increasing downward slopes, due to the formation of a dual
inhibitor-enzyme complex in addition to the complexes
formed between enzyme and single inhibitors. If binding of
one inhibitor prevents binding of a second inhibitor, how-
ever, then inhibition is mutually exclusive and the addition
of a second inhibitor has no effect on the slopes of the lines
observed.
Previous studies have shown that incorporation ofACGTP
or DHPGTP into template may result in product inhibition
(10, 12) and possibly enzyme inactivation (16) when high
concentrations of ACGTP are used. In the present study
reaction velocities in the presence of ACGTP and DHPGTP
decreased relative to controls upon prolonged incubation.
However, reaction velocities in the presence of 3, 6, and 9
nM ACGTP remained constant for at least 10 min and
reaction velocities were constant for at least 20 min in the
presence of 30 nM DHPGTP. Reaction velocities in the
presence of 60 and 90 nM DHPGTP were constant only if
aphidicolin or PFA was present (data not shown). Under
these conditions steady state was achieved, so DNA poly-
merase reactions involving ACGTP were incubated for only
10 min, whereas those involving DHPGTP in combination
with aphidicolin or PFA were incubated for 20 min.
The interaction of HSV DNA polymerase with PFA and
ACGTP or DHPGTP during DNA synthesis is shown in Fig.
1. The Ki value for PFA was 0.6 puM. This was determined
by the intercept (-Ki) of the line obtained in the absence of
a second inhibitor, since PFA is noncompetitive with sub-
strate, and is in reasonable agreement with previously pub-
lished values (9, 11, 20, 22). Since ACGTP and DHPGTP are
competitive with dGTP, which was used at a concentration
approximately 2.5-fold above the Ki,m apparent Ki values of
10 nM for ACGTP and 60 nM for DHPGTP are higher than
the true Ki values of 3 and 30 nM published previously (10,
12). A set of parallel lines were observed, indicating that
inhibition of DNA polymerase by acyclic nucleotide and
PFA was mutually exclusive (25). This suggests that the
PFA binding site on the DNA polymerase molecule may be
overlapping with the acyclic nucleotide binding site.
A similar set of experiments, designed to investigate the
interaction of HSV DNA polymerase with aphidicolin and
acyclic NTP, is shown in Fig. 2. Reciprocal plots of reaction
velocities indicated that inhibition of DNA synthesis was
mutually exclu§jve with apparent Ki values of 2 to 5 ,uM,
lOnM and 60 nM for aphidicolin, ACGTP, and DHPGTP.
Since aphidicolin is noncompetitive with dGTP (13), appar-
ent K, values were estimated by the abscissa intercept
method.
Dual inhibitor studies were also perfornmed to examine the
interaction of PFA and aphidicolin with HSV DNA polymer-
ase. The results presented in Fig. 3A indicate mutually
exclusive inhibition of DNA polymerase activity with a Ki
value of 0.6 p.M for PFA and an apparent K, of 5 pM for
aphidicolin. This experiment was also performed with
[3H]dTTP as labeled precursor and mutually exclusive kinet-
ics were observed (data not shown). In addition, the effect of
PFA and aphidicolin upon hydrolysis of DNA by HSV DNA
polymerase-associated nuclease is shown in Fig. 3B. The
interaction was mutually exclusive with Ki values of 8 and
0.22 p.M for PFA and aphidicolin. Since neither PFA nor
aphidicolin is competitive with DNA substrate (9, 11, 13,
20-22) Ki values were determined by the abscissa intercept
and by replot of ordinate intercepts.
These results indicated that PFA, aphidicolin, ACGTP,
and DHPGTP acted upon HSV DNA polymerase in such
ways that inhibition of nucleotide incorporation by one
compound interfered with inhibition by a second compound.
This was also true for inhibition of DNA polymerase-asso-
ciated nuclease activity by PFA and aphidicolin. This does
not prove that binding sites for the three classes of com-
pound are identical or that they are located physically close
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together, since mutually exclusive kinetics could result from
allosteric effects. However, if the binding sites are overlap-
ping it would be possible for a single change at the active site
of DNA polymerase to result in altered affinities for PFA,
aphidicolin, and acyclic NTPs; for example, if a basic amino
acid at the active site is involved in the binding of PFA and
acyclic NTP, it is conceivable that a change to a more
neutral amino acid would lessen the binding affinities of
acidic compounds such as phosphonoacetate and acyclic
NTPs, whereas affinities to hydrophobic compounds such as
aphidicolin would increase. In this event, the reported
cross-resistance of PFA-resistant virus strains and DNA
polymerases isolated from these strains to inhibition by
acyclic nucleotide (5, 6, 8, 14, 19, 24) and collateral hyper-
sensitivity to aphidicolin (2, 4, 18) would be more than
coincidental.
Based on the mutually exclusive interaction of PFA,
aphidicolin, and acyclic NTP with virus DNA polymerase,
we would predict that inhibition of virus by combinations of
these compounds should not be more than additive. How-
ever, several reports have indicated synergistic interaction
of PFA and ACG (7, 26). One possible explanation for these
observations is that these compounds may act by other
mechanisms in addition to inhibition of HSV DNA polymer-
ase. There is no evidence at present to support this. It is also
possible that the synergistic antiviral activity, which was
observed using plaque reduction assays, reflects the action
of combinations of these compounds against different popu-
lations of virus variants in the virus preparations used. It will
be of interest to see if similar results are obtained with yield
reduction assays.
The kinetic data presented in these studies suggest that the
binding sites for these compounds could be physically over-
lapping. High-resolution mapping of drug resistance loci of






FIG. 2. Inhibition of virus DNA polymerase by Ce
aphidicolin and acyclic nucleotide. DNA polymerase
assayed under conditions described in the text. Aj
present at the concentrations indicated. (A) ACGTP
produce the following concentrations: 0 (0), 3 (A), 6
nM. (B) DHPGTP was added to produce the follow
tions: 0 (0), 30 (-), 60 (A), and 90 (0) nM. React
expressed as picomoles of dGMP incorporated per ho
fitted to the data by the method of least squares.
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FIG. 3. Inhibition of virus DNA polymerase and polymerase-as-
sociated nuclease activity by combinations of aphidicolin and PFA.
(A) DNA polymerase (0.03 U) was assayed under conditions de-
scribed in the text. Aphidicolin was present at the concentrations
indicated. PFA was added to produce the following concentrations:
0 (0), 0.2 (U), 0.4 (A), and 0.6 (0) ,uM. Reaction velocity is
expressed as picomoles of dGMP incorporated per hour. (B) DNA
polymerase-associated nuclease was assayed under conditions de-
scribed in the text. Reaction mixtures contained 0.05 U of DNA
polymerase (assayed under standard DNA polymerase conditions)
and aphidicolin was present at the concentrations indicated. PFA
was added to produce the following concentrations: 0 (0), 5 (i), 10
(A), and 15 (0) ,uM. Reaction velocity is expressed as picomoles of
dGMP released from acid-precipitable polynucleotide per hour.
Lines were fitted to the data by the method of least squares.
purified to homogeneity will be necessary to further investi-
gate this possibility. For the present time, these data shed
light on the complexity of virus DNA polymerase and should
be considered during the design of combination chemother-
apy protocols.
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